Oncolytic virotherapy: the questions and the promise
Oncolytic Virotherapy, 2013 Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire +4 more sources
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting. Observations: A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy
Inta Jaunalksne +4 more
doaj
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses [PDF]
, 2006 Giulia Fulci +10 more
openalex +1 more source
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies [PDF]
, 2006 Huy Ong +4 more
openalex +1 more source
Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias [PDF]
, 2006 Rienk E. Jeeninga +3 more
openalex +1 more source
949. Oncolytic Autonomous Parvovirus (rH1-yCD) Targeting with P4/Carcinoembryonic Antigen Chimeric Promoter for Virotherapy of Pancreatic Cancer [PDF]
, 2006 Soukaina Réjiba +2 more
openalex +1 more source
310. Antitumor Effect of Telomerase-Specific Virotherapy in Pleural Dissemination of Human Malignant Mesothelioma [PDF]
, 2006 Yuichi Watanabe +8 more
openalex +1 more source
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene [PDF]
, 2007 Sricharan Chalikonda +10 more
openalex +1 more source
Virotherapy in Head and Neck Cancer
Oral Oncology ReportsHead and neck cancer, comprising a diverse group of malignancies, presents significant challenges in terms of treatment efficacy and patient outcomes.
Zhan Wang
doaj
Redemption for the Field of Oncolytic Virotherapy
Molecular Therapy, 2011 The field of targeted and transgene-armed oncolytic viruses has been through a cycle of boom (mid-1990s) and bust (the early 2000s). In January 2011, however, Amgen—the biggest independent biotechnology company in the world—jumped headfirst into the field by acquiring Biovex for $425 million and promising potential success-based milestone payments of ...
openaire +3 more sources